KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Cash & Equivalents (2016 - 2025)

Biogen (BIIB) has 17 years of Cash & Equivalents data on record, last reported at $2.8 billion in Q2 2025.

  • For Q2 2025, Cash & Equivalents rose 44.52% year-over-year to $2.8 billion; the TTM value through Jun 2025 reached $2.8 billion, up 44.52%, while the annual FY2024 figure was $2.4 billion, 126.21% up from the prior year.
  • Cash & Equivalents reached $2.8 billion in Q2 2025 per BIIB's latest filing, up from $2.6 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.7 billion in Q3 2022 and bottomed at $1.0 billion in Q4 2023.
  • Average Cash & Equivalents over 5 years is $2.2 billion, with a median of $2.3 billion recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: crashed 69.29% in 2023, then soared 141.84% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $2.3 billion in 2021, then soared by 51.2% to $3.4 billion in 2022, then plummeted by 69.29% to $1.0 billion in 2023, then skyrocketed by 126.21% to $2.4 billion in 2024, then rose by 16.16% to $2.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $2.8 billion in Q2 2025, $2.6 billion in Q1 2025, and $2.4 billion in Q4 2024.